| Business Summary | | Salix
Pharmaceuticals,
Ltd.
is
a
market-driven
specialty
pharmaceutical
company
focused
on
the
needs
of
physicians
specializing
in
gastroenterology.
The
Company's
strategy
is
to
identify
and
acquire
products
that
have
near-term
commercial
potential,
and
apply
its
regulatory,
product
development
and
sales
and
marketing
expertise
to
commercialize
these
products.
The
Company
selects
products
to
serve
a
gastrointestinal
disease
in
need
of
new
treatments,
and
have
the
potential
for
rapid
regulatory
approval.
The
Company's
first
two
products
are
balsalazide
disodium,
which
is
marketed
in
the
United
States
under
the
brand
name
Colazal,
and
in
the
United
Kingdom,
Sweden
and
Denmark
under
the
brand
names
Colazide,
Colazid
and
Premid,
respectively,
and
rifaximin,
which
is
under
development. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Salix
Pharmaceuticals,
Ltd.
develops
and
markets
prescription
pharmaceutical
products
for
the
treatment
of
gastrointestinal
diseases.
For
the
six
months
ended
6/30/01,
revenues
totalled
$10.7
million,
up
from
$1.7
million.
Net
loss
totalled
$7.2
million,
up
from
$2.1
million.
Revenues
benefitted
from
sales
of
COLAZAL(TM).
Higher
loss
reflects
increased
selling,
general
and
administrative
expenses
related
to
the
launch
of
COLAZAL(TM)
in
the
United
States. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Randy Hamilton, 46 Chairman | $227K | $89K | Robert Ruscher, 40 Pres,
CEO, Director | 244K | 158K | Adam Derbyshire, 35 CFO,
VP of Fin. and Admin., Sec. | -- | -- | Carolyn Logan, 52 Sr.
VP of Sales and Marketing | -- | -- | Lorin Johnson, Ph.D., 48 Sr.
VP, Devel. and CSO | 186K | 72K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|